POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES (11.19.2021, 4:50pm CEST, WHO):   India 11,106    Brazil 11,977    United Kingdom 46,858    Russia 37,156    Turkey 22,234    France 19,840    Argentina 1,553    Germany 52,970    Spain 3,932    Columbia 2,257    Italy 10,645    Mexico 3,836    Ukraine 20,050    Poland 23,242    Philippines 1,297    Malaysia 6,380    Netherlands 23,680    Peru 1,370    Thailand 6,855    Czechia 13,374    Canada 2,448    Romania 3,076    Chile 2,611    Serbia 3,219    Sweden 1,210    Portugal 2,398    Vietnam 10,223    Kazakhstan 1,272    Austria 14,212    Hungary 11,289    Greece 7,276    Georgia 4,278    Bulgaria 2,785    Belarus 1,844    Slovakia 7,418    Azerbaijan 2,124    Croatia 7,270    Bolivia 1,119    Ireland 4,646    Lithuania 1,847    Denmark 4,013    South Korea 3,034    Slovenia 3,662    Latvia 1,221    Laos 1,401    China 31    New Zealand 200    Australia 1,302   

Half of commercial rapid rabies tests don't detect rabies

Staff writer |
Rabies virus (RABV) transmitted by dogs is responsible for an estimated 60,000 human deaths per year, especially in Asia and Africa.

Article continues below






If humans bitten by a rabid animal are treated quickly, the disease can usually be prevented. Such post-exposure prophylaxis is expensive and should be reserved for bites from animals with confirmed infection, but testing dogs for rabies in resource-poor settings is challenging.

A study reports that six commercially available rapid rabies tests - which could make testing dogs much easier - fail to reproducibly yield accurate results.

The gold standard for rabies diagnosis is the fluorescence antibody test (FAT), which requires that brain tissue is fixed on microscope slides, stained with fluorescently labelled antibodies, and examined under a fluorescence microscope.

Alternative diagnostics include various assays to detect virus, antigen or viral RNA, the latter based on PCR technology. All of these tests require laboratory equipment, trained staff, and temperature-sensitive reagents.

In response to a call from WHO for better tests for the rapid and economical diagnosis of RABV, several alternatives have been developed.

Lateral flow devices (LFDs) have great potential as field tests: they are rapid and easy to use without the need for special training for implementation and evaluation, and can be shipped and stored at ambient temperatures.

Early studies of rabies LFDs yielded promising results and raised hope for better rabies diagnostic capacity in resource-limited settings.

Following the initially reported prototype, numerous LFDs for rabies diagnosis are now commercially available. Because comprehensive evaluations of these tests have not been published, Conrad Freuling, from the Friedrich-Loeffler-Institute in Greifswald, Germany, and colleagues in this study compared six commercially available rabies LFDs.

They examined the sensitivity of the tests (their ability to exclude rabies infection accurately) as well as their specificity (reflecting an accurate positive diagnosis) in comparison with FAT and PCR in over 100 samples from experimentally infected animals and animals infected in the wild.

While all six tests showed good specificity (i.e., they did not come up with "false positives"), the researchers found that none of them demonstrated good sensitivity across the different sample sets.

In fact, more than half of all positive samples (i.e., those with positive FAT and PCR results) yielded "false negative" LFD results. Some LFD tests did better than others, and in some cases specific batches of the same test did better than others, but overall the results were disappointing.

On a positive note, the researchers report that viral RNA can be stored and eventually extracted from the LFDs using standard procedures available at molecular diagnostic laboratories.

In fact, they were able to detect viral RNA after six weeks of storage at room temperature. Thus test strips could be easily shipped by regular mail to a specialized laboratory, not only for a confirmation of the results, but also further characterization of virus isolates.


What to read next

FDA warns ovarian cancer tests not reliable
Pneumonia finger clip and better diagnostic tests could save thousands of lives
New sensor can quickly and cost-effectively detect deadly E.coli